References
- IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation, 2015. Available at: http://www.diabetesatlas.org [Last accessed 17 May 2017]
- Centers for Disease Control and Prevention. National Diabetes Statistics Report 2017. Available at: https://www.cdc.gov/diabetes/data/index.html [Last accessed 26 July 2017]
- Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diabetes Rep 2013;13:814-23
- Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. National Center for Health Statistics. Available at: https://www.cdc.gov/nchs/data/hus/hus15.pdf [Last accessed 19 May 2017]
- Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens 1995;8:657-65
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016;133:e38-360
- Howard G, Cushman M, Kissela BM, et al. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke 2011;42:3369-75
- Kirk JK, D’Agostino RB Jr, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29:2130-6
- Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the National Health and Nutrition Examination Survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017;10(1). pii: e003166. doi: 10.1161/CIRCOUTCOMES.116.003166
- Quick facts: people (2010 through 2015). US Census Bureau. Available at: https://www.census.gov/quickfacts/table/RHI225215/00 [Last accessed 25 May 2017]
- Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin 2015;31:913-23
- Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products (August 2013). US Department of Health and Human Services Food and Drug Administration. Available at: https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM365544.pdf [Last accessed 24 May 2017]
- Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. Lancet Diabetes Endocrinol 2017;5:13
- Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 2015;97:263-73
- Anderson JE, Wright EE Jr, Shaefer CF Jr. Empagliflozin: role in treatment options for patients with type 2 diabetes mellitus. Diabetes Ther 2017;8:33-53
- Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59
- Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38:420-8
- Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:1180-93
- Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 2016;25:81-6
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34
- O’Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731-68
- Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15
- Mersha TB, Abebe T. Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics 2015;9:1
- US Food and Drug Administration. Collection of Race and Ethnicity Data in Clinical Trials. Guidance for Industry and Food and Drug Administration Staff. October 2016. Available at: https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126396.pdf [Last accessed 8 November 2017]
- Cavaco I, Reis R, Gil JP, Ribeiro V. CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med 2003;41:606-9
- Scott SA, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010;11:781-91
- McCormack S, Grant SF. Genetics of obesity and type 2 diabetes in African Americans. J Obesity 2013;2013:396416
- Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors – an Endocrine Society scientific statement. J Clin Endocrinol Metab 2012;97:E1579-639